Home Science Drug combination for stage IV melanoma shows success in trial

Drug combination for stage IV melanoma shows success in trial

40

A new study examined the combination of the common immunotherapy drug pembrolizumab (Keytruda) with all-trans retinoic acid (ATRA), a chemotherapy drug that targets myeloid-derived suppressor cells. Researchers found that the drug combination is effective, with an overall response rate of 71%. Fifty percent of patients experienced a complete response, and the one-year overall survival rate was 80%.

Source: ScienceDaily.com